Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of bacillus coagulans JA845 in preparation of medicine for preventing and/or treating Alzheimer's disease

A technology for Bacillus coagulans and Alzheimer's disease, applied in drug combinations, microorganism-based methods, biochemical equipment and methods, etc., can solve problems such as inability to cure AD, reduce neuronal degeneration, and reduce learning and memory-related problems. Injury, improve the effect of AD pathological features

Active Publication Date: 2021-06-08
JILIN ACAD OF AGRI SCI
View PDF11 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Current medical treatment can only delay the development of symptoms in AD patients, but cannot cure AD

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of bacillus coagulans JA845 in preparation of medicine for preventing and/or treating Alzheimer's disease
  • Application of bacillus coagulans JA845 in preparation of medicine for preventing and/or treating Alzheimer's disease
  • Application of bacillus coagulans JA845 in preparation of medicine for preventing and/or treating Alzheimer's disease

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0052] The preparation method of D-galactose solution: take D-galactose powder and prepare D-galactose solution with a concentration of 12mg / ml with physiological saline.

[0053] Aluminum chloride: purchased from Sinopharm Chemical Reagent Co., Ltd.

[0054] The preparation method of the aluminum chloride solution: take the aluminum chloride powder and prepare an aluminum chloride solution with a concentration of 2 mg / ml with physiological saline.

Embodiment 1

[0055] The preparation of embodiment 1 bacillus coagulans (Bacillus coagulans) JA845 bacterial suspension

[0056] 1. Strain activation: Pick the freeze-dried bacterial powder of Bacillus coagulans (Bacillus coagulans) JA845, inoculate it in LB liquid medium, and cultivate the activated strain in a shaking incubator at 50°C and 180 rpm for 8-9 hours.

[0057] 2. Subculture of the strain: take the activated culture medium of the strain, inoculate it into a new LB liquid medium with a 3% inoculation amount, culture it in a shaking incubator at 50°C and 180rpm for 8-9 hours, repeat this step to passage the strain Repeat this step 3 times to expand the culture to obtain more bacterial liquid.

[0058] 3. Calculation of the number of viable bacteria: Dilute the bacterial solution by 10 and 10 respectively by coating plate counting method 2 、10 3 、10 4 、10 5 、10 6 、10 7 、10 8 and 10 9 times, the diluted bacterial solution was evenly spread on the surface of LB solid medium, ...

Embodiment 2

[0060] Example 2 Effect of Bacillus coagulans (Bacillus coagulans) JA845 on preventing and treating Alzheimer's disease

[0061] 1. Materials and methods:

[0062] 1. Establishment of Alzheimer's disease mouse model and experimental grouping

[0063] 30 SPF-grade ICR mice, half male and half female, weighing 20±5 (g), kept at constant temperature (20±2°C) and constant humidity (40-60%), kept circadian rhythm for 12 hours, free to eat and drink, and fed normally for one week , were randomly divided into 3 groups according to body weight and sex: blank control group (n=10), AD model group (n=10), JA845 prevention group (n=10), AD model group was fed with sterile normal saline every day, 90min Afterwards, intraperitoneal injection of D-galactose solution (120mg / kg), intragastric administration of AlCl 3 solution (20mg / kg); the JA845 prevention group was fed intragastrically with Bacillus coagulans JA845 bacterial suspension every day, and after 90min, intraperitoneally injected...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to an application of bacillus coagulans JA845 in preparation of medicine for preventing and / or treating Alzheimer's disease, and belongs to the field of biology. The bacillus coagulans JA845 is preserved in China General Microbiological Culture Collection Center on April 14, 2020, and the preservation number is CGMCC No.19576. Bacillus coagulans JA845 is prepared into a bacterial suspension, and the viable count is greater than or equal to 1*10<9> CFU / ml. In the invention, the bacillus coagulans JA845 prevents and treats the Alzheimer's disease by improving the learning and memory ability, relieving the damage degree of neuronal cells, reducing A beta deposition, regulating intestinal flora and the like. The invention provides a new idea for clinically preventing and treating Alzheimer's disease, and has wide application prospect and popularization value.

Description

technical field [0001] The invention belongs to the field of biotechnology, and in particular relates to the application of a bacillus coagulans JA845 in the preparation of drugs for preventing and / or treating Alzheimer's disease. Background technique [0002] Dementia is a syndrome characterized by a decline in memory, thinking, behavior and ability to perform daily activities. Alzheimer's disease (AD) is a common type of senile dementia. The main pathological features of AD include deposition of β-amyloid protein (Aβ) to form neuritic plaques, hyperphosphorylation of Tau protein leading to neurofibrillary tangles, loss of neurons and synapses, and activation of microglial cells. There are approximately 50 million AD patients in the world, with 10 million new cases each year. It is predicted that the total number of AD patients will reach 82 million by 2030 and 152 million by 2050. Alzheimer's disease has a profound impact on the patients themselves, as well as their car...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K35/742A61P25/28C12N1/20C12R1/07
CPCA61K35/742A61P25/28C12N1/20
Inventor 赵子健李盛钰杨舸赵玉娟王超高磊
Owner JILIN ACAD OF AGRI SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com